MEGHANA TRIVEDI to Treatment Outcome
This is a "connection" page, showing publications MEGHANA TRIVEDI has written about Treatment Outcome.
Connection Strength
0.146
-
Neratinib in HER2-Positive Breast Cancer Patients. Ann Pharmacother. 2019 06; 53(6):612-620.
Score: 0.036
-
The incidence of tumor cell contamination of peripheral blood stem cells: a meta-analysis to evaluate the impact of mobilization regimens and the influence on outcomes in breast cancer patients. Acta Haematol. 2014; 131(3):133-40.
Score: 0.025
-
Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer. Pharmacotherapy. 2013 Oct; 33(10):1126-9.
Score: 0.025
-
Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011 Oct; 20 Suppl 3:S42-9.
Score: 0.022
-
Review and revision of clinical practice of using G-CSF after autologous and allogeneic hematopoietic stem cell transplantation at UCSD. J Oncol Pharm Pract. 2011 Jun; 17(2):85-90.
Score: 0.019
-
Optimal use of G-CSF administration after hematopoietic SCT. Bone Marrow Transplant. 2009 Jun; 43(12):895-908.
Score: 0.018